$RNA

Atrium Therapeutics, Inc.

CIK:0002093101|SEC Filings

Condensed Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Collaboration revenue	$ 3,004,000	$ 3,847,000	$ 22,639,000	$ 5,420,000
Operating expenses:
Research and development	15,343,000	13,293,000	32,000,000	20,230,000
General and administrative	10,279,000	3,418,000	30,537,000	5,506,000
Total operating expenses	25,622,000	16,711,000	62,537,000	25,736,000
Loss from operations	(22,618,000)	(12,864,000)	(39,898,000)	(20,316,000)
Other income (expense)
Interest income	2,104,000	0	2,757,000	0
Other income (expense), net	328,000	(15,000)	322,000	(12,000)
Total other income (expense)	2,432,000	(15,000)	3,079,000	(12,000)
Net loss	$ (20,186,000)	$ (12,879,000)	$ (36,819,000)	$ (20,328,000)
Basic net loss per common share	$ (1.18)	$ (0.75)	$ (2.15)	$ (1.19)
Diluted net loss per common share	$ (1.18)	$ (0.75)	$ (2.15)	$ (1.19)
Weighted-average common shares outstanding used in the calculation of net loss per common share,basic	17,106	17,106	17,106	17,106
Weighted-average common shares outstanding used in the calculation of net loss per common share, diluted	17,106	17,106	17,106	17,106
Other comprehensive loss:
Net unrealized loss on short-term investments	$ (235,000)	$ 0	$ (235,000)	$ 0
Comprehensive loss	$ (20,421,000)	$ (12,879,000)	$ (37,054,000)	$ (20,328,000)

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (36,819)	$ (20,328)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	494	132
Stock-based compensation expense	13,106	2,910
Non-cash operating lease costs	1,595	135
Amortization of premiums and discounts on short-term investments, net	(250)	0
Changes in operating assets and liabilities:
Prepaid assets	(2,971)	(829)
Other current assets	(5,024)	(1,302)
Accounts payable	(885)	(221)
Accrued liabilities	4,334	3,171
Accrued compensation	815	1,236
Lease liabilities	(2,026)	(1,919)
Deferred revenues	(7,639)	(5,421)
Other long-term liabilities	201	(574)
Net cash used in operating activities	(35,069)	(23,010)
Cash flows from investing activities
Purchases of short-term investments	(191,551)
Purchases of property and equipment	(2,134)	(266)
Net cash used in investing activities	(193,685)	(266)
Cash flows from financing activities
Net transfers from Former Parent	301,505	23,276
Net cash provided by financing activities	301,505	23,276
Net increase in cash, cash equivalents, and restricted cash	72,751	0
Cash, cash equivalents and restricted cash, at beginning of period	0	0
Cash, cash equivalents and restricted cash, at end of period	72,751	0
Reconciliation of cash, cash equivalents and restricted cash, at end of period:
Cash and cash equivalents	72,334	0
Restricted cash included in current assets	311	0
Restricted cash included in non-current assets	106	0
Total cash, cash equivalents and restricted cash	72,751	0
Supplemental schedule of noncash investing and financing activities:
Costs incurred, but not paid, in connection with purchases of property and equipment included in accounts payable and accrued liabilities	0	109
Net assets distributed from Former Parent	0	742
Reclassification of deficit from Former Parent	$ 221,940	$ 0

Condensed Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 72,334,000	$ 0
Short term investments	191,566,000	0
Prepaid assets	4,506,000	1,535,000
Restricted cash, current portion	311,000	0
Other current assets	6,334,000	1,310,000
Total current assets	275,051,000	2,845,000
Restricted cash, net of current portion	106,000	0
Property and equipment, net	4,066,000	2,724,000
Right-of-use asset	1,289,000	2,784,000
Total assets	280,512,000	8,353,000
Current liabilities:
Accounts payable	3,513,000	4,398,000
Accrued liabilities	13,312,000	8,945,000
Accrued compensation	3,962,000	3,147,000
Lease liabilities	1,683,000	3,672,000
Deferred revenue, current portion	9,038,000	21,639,000
Total current liabilities	31,508,000	41,801,000
Deferred revenue, net of current portion	33,653,000	28,691,000
Other long-term liabilities	775,000	574,000
Total liabilities	65,936,000	71,066,000
Commitments and contingencies
Stockholders' equity/ Former Parent's deficit:
Preferred stock, $0.001 par value: 40,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value: 400,000 shares authorized; 17,106 shares issued and outstanding as of June 30, 2026, and no shares authorized, issued, or outstanding as of December 31, 2025	16,000	0
Additional paid-in capital	222,853,000	0
Accumulated deficit	(8,058,000)	0
Accumulated other comprehensive loss, net	(235,000)	0
Net investment from Former Parent	0	(62,713,000)
Total stockholders' equity / Former Parent's deficit	214,576,000	(62,713,000)
Total liabilities and Stockholders' equity / Former Parent's deficit	$ 280,512,000	$ 8,353,000